Memory function often declines with age, and is believed to deteriorate initially because of changes in synaptic function rather than loss of neurons. Some individuals then go on to develop Alzheimer's disease with neurodegeneration. Here we use Tg2576 mice, which express a human amyloid-beta precursor protein (APP) variant linked to Alzheimer's disease, to investigate the cause of memory decline in the absence of neurodegeneration or amyloid-beta protein amyloidosis. Young Tg2576 mice (< 6 months old) have normal memory and lack neuropathology, middle-aged mice (6-14 months old) develop memory deficits without neuronal loss, and old mice (> 14 months old) form abundant neuritic plaques containing amyloid-beta (refs 3-6). We found that memory deficits in middle-aged Tg2576 mice are caused by the extracellular accumulation of a 56-kDa soluble amyloid-beta assembly, which we term Abeta*56 (Abeta star 56). Abeta*56 purified from the brains of impaired Tg2576 mice disrupts memory when administered to young rats. We propose that Abeta*56 impairs memory independently of plaques or neuronal loss, and may contribute to cognitive deficits associated with Alzheimer's disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nature04533 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hearing modulation affects Alzheimer's disease progression linked to brain inflammation: a study in mouse models.
Mol Med
December 2024
Department of Otolaryngology-Head and Neck Surgery, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jaebong-Ro, Dong-Gu, Gwangju, 61469, Republic of Korea.
Background: Recent studies have identified hearing loss (HL) as a primary risk factor for Alzheimer's disease (AD) onset. However, the mechanisms linking HL to AD are not fully understood. This study explored the effects of drug-induced hearing loss (DIHL) on the expression of proteins associated with AD progression in mouse models.
View Article and Find Full Text PDFGut microbiota dysbiosis in Alzheimer's disease (AD): Insights from human clinical studies and the mouse AD models.
Physiol Behav
December 2024
Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA; Deptment of Neuroscience & Regenerative Medicine, Augusta, GA 30912, USA; College of Agriculture, Food, and Natural Resources, Prairie View A&M University, Prairie View, TX 77446, USA; Centre for Healthy Aging, Medical College of Georgia, Augusta University, Augusta, GA, USA; Department of Cell Biology and Anatomy, Medical College of Georgia, Augusta University, GA, USA; Department of Orthopedic Surgery, Medical College of Georgia, Augusta University, Augusta, GA, USA. Electronic address:
Alzheimer's Disease (AD) is a debilitating neurocognitive disorder with an unclear underlying mechanism. Recent studies have implicated gut microbiota dysbiosis with the onset and progression of AD. The connection between gut microbiota and AD can significantly affect the prevention and treatment of AD patients.
View Article and Find Full Text PDFFAAH Inhibition Counteracts Neuroinflammation via Autophagy Recovery in AD Models.
Int J Mol Sci
November 2024
Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy.
Article Synopsis
- Endocannabinoids show promise in reducing neuroinflammation related to Alzheimer's disease (AD) by potentially rebalancing autophagic mechanisms.
- Researchers administered URB597, an FAAH inhibitor that increases anandamide levels, to both microglial cultures and Tg2576 transgenic mice.
- The treatment led to a shift in microglia toward an anti-inflammatory state, reduced amyloid plaque formation, and restored key autophagy markers, indicating a possible therapeutic approach for AD.
Alterations of endocannabinoid signaling and microglia reactivity in the retinas of AD-like mice precede the onset of hippocampal β-amyloid plaques.
J Neurochem
November 2024
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Extra-cerebral manifestations of Alzheimer's disease (AD) develop in the retina, which is, therefore, considered a "window to the brain". Recent studies demonstrated the dysregulation of the endocannabinoid (eCB) system (ECS) in AD brain. Here, we explored the possible alterations of ECS and the onset of gliosis in the retina of AD-like mice.
View Article and Find Full Text PDFmCLAS adaptively rescues disease-specific sleep and wake phenotypes in neurodegeneration.
Sleep Med
December 2024
Department of Neurology, University Hospital Zurich (USZ), Switzerland; Neuroscience Center Zurich (ZNZ), Switzerland; Center of Competence Sleep and Health, University of Zurich (UZH), Switzerland. Electronic address:
Article Synopsis
- Sleep changes are common in Alzheimer's and Parkinson's diseases, affecting brain health during deep sleep.
- A new method called mouse closed-loop auditory stimulation (mCLAS) has been developed to enhance slow-wave activity during deep sleep in models of these diseases.
- Initial findings show that mCLAS can improve sleep patterns in mice, with different effects seen in Alzheimer's versus Parkinson's models, suggesting potential for future sleep-based therapies in neurodegenerative conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!